Rifaximin in Patients With Monoclonal Gammopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-15

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

NCT00275613

Glomerulonephritis, Membranoproliferative

COMPLETED PHASE1

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

NCT00072592

Wegener's Granulomatosis

COMPLETED PHASE1

Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

NCT00258180

Diarrhea Gastrointestinal Complications Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE2

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

NCT02966353

Primary Myelofibrosis Post-Polycythemia Vera-Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis

COMPLETED PHASE2

Rituximab in the Treatment of Patients With Bullous Pemphigoid

NCT00286325

Bullous Pemphigoid

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To evaluate the effect of a 2-week course of rifaximin on clonal immunoglobulin (Ig) in patients with monoclonal gammopathy.

SECONDARY OBJECTIVES:

I. To evaluate safety and tolerability of a 2-week course of rifaximin.

II. To evaluate changes in stool microbiota by 16S ribosomal ribonucleic acid (rRNA) gene (16S) sequencing.

III. To evaluate changes in gammopathy as assessed by changes in clonal Ig and/or plasma cells.

OUTLINE:

Patients receive rifaximin orally (PO) thrice daily (TID) on days 1-14 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 8 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgA Monoclonal Gammopathy IgG Monoclonal Gammopathy IgM Monoclonal Gammopathy Light Chain Deposition Disease Monoclonal Gammopathy Smoldering Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia Gammopathy, Monoclonal Gammopathy Igg

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (rifaximin)

Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Rifaximin

Intervention Type DRUG

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rifaximin

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xifaxan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of monoclonal gammopathy of undetermined significance based on International Myeloma Working Group (IMWG) criteria
* Patients will be enrolled into one of 3 cohorts:

* Cohort A: IgA gammopathy
* Cohort B: IgG gammopathy / or light chain gammopathy
* Cohort C: IgM gammopathy / asymptomatic macroglobulinemia
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

* Patients who have received antibiotics within last 3 weeks
* Patients who are receiving any other investigational agents for gammopathy. Patients with clinical myeloma requiring anti-myeloma therapy are also excluded
* History of allergic reactions or intolerance attributed to rifaximin or compounds of similar chemical or biologic composition to antibiotic under study
* The effects of rifaximin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rifaximin administration

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No